Preview

Modern Rheumatology Journal

Advanced search

Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis

https://doi.org/10.14412/1996-7012-2012-715

Abstract

The impact of a 4-week course of therapy with Uralyt-U (potassium-sodium hydrocitrate) on uric acid (UA) metabolic parameters was studied in patients with gout and nephrolithiasis. Elevated daily urinary excretion of UA was found to be directly correlated with its lower serum level after 4-week therapy with Uralyt-U (p < 0.05), resulting in improvement and normalization of UA metabolism. Uralyt-U therapy is safe and causes no worsening of the parameters of hepatic and renal function and electrolyte exchange.

References

1. <div><p>Kramer H.M., Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988—1994. Am J Kidney Dis 2002; 40: 37—42.</p><p>Барскова В.Г., Мукагова М.В. Современные представления о патогенезе и методах коррекции уратного нефролитиаза у больных подагрой. Совр. ревматол. 2011; 4: 39—44.</p><p>Perez-Ruiz F., Calaborozo M., Herrero-Beites A.M. et al. Improvement of Renal Function in Patients in with Chronic Gout after Proper Control of Hyper—uricemia and Gouty Bouts. Nephron 2000; 86: 287—91.</p><p>Pearle M.S., Calhoun E., Curhan G.C. Urolithiasis. In: Litwin M.S., Saigal C.S., eds. Urologic Diseases in America. Washington, DC: NIDDK 2007; 283—319.</p><p>Wallace K.L., Riedel A.A., Joseph-Ridge N. et al. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in amanaged care population. J Rheumatol 2004; 31: 1582—7.</p><p>Murray J., Favus M. Chapter 14. Nephrolithiasis. In: Diseases of bone and calcium metabolism. 2010 http://www.endotext.org/parathyroid/parat hyroidcontributors.htm</p><p>Ounissy M., Gargueh T., Mahfoudhi M. et al. Nephrolithiasis-induced end stage renal disease. Int J Nephrol Renovasc Dis 2010; 3: 21—6.</p><p>Kang D.H., Nakagawa T., Feng L. et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888—97.</p><p>Nakagawa T., Mazzali M., Kang D.H. et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003; 23: 2—7.</p><p>Sakhaee K. Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens 2008; 17: 304—9.</p><p>Shimizu T., Hori H. The prevalence of nephrolithiasis in patients with primary gout: a cross-sectional study using helical computed tomography. J Rheum 2009; 36: 1958—62.</p><p>Alvares-Nemegyei J., Medino-Escobedo M., Villanueva-Jorge S. et al. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed? J Rheum 2005; 32: 2189—91.</p><p>Tin C. Ngo, Dean G. Assimos. Uric acid nephrolithiasis: recent progress and future directions. Rev Urol 2007; 9(1): 17—27.</p><p>Елисеев М.С., Барскова В.Г. Метаболический синдром при подагре. Вестник РАМН 2008; 6: 29—33.</p><p>Zhang W., Doherty M., Bardin T. et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312—24.</p><p>Pak C.Y. Pharmacotherapy of kidney stones. Expert Opin Pharmacother 2008; 9(9): 1509—18.</p><p>Тареев Е.М. Нефриты. М.: Медгиз, 1956; 668 с.</p><p>Joan H., Fredric L. Coe. Evidence for durable kidney stone prevention over several dacades. BJU Int 2009: 5; 103(9): 1238—46.</p><p>Thorburn A.W., Storlien L.H., Jenkins A.B. et al. Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am J Clin Nutr 1989; 49: 1155—63.</p><p>Елисеев М.С., Барскова В.Г. Применение цитратной смеси Блемарен у больных подагрой с нефролитиазом. Совр. ревматол. 2008; 3: 35—40.</p><p>Riedel A.A., Nelson M., Joseph-Ridge N. et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004; 31(8): 1575—81.</p><p>Briesacher B.A., Andrade S.E., Fouayzi H. et al. Medication adherence across seven medical conditions. Pharmacotherapy 2008; 28: 437—43.</p></div><br />


Review

For citations:


Eliseyev MS, Denisov IS, Barskova VG. Clinical experience with Uralyt-U used in patients with gout and nephrolithiasis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2012;6(1):44-48. (In Russ.) https://doi.org/10.14412/1996-7012-2012-715

Views: 2382


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)